SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 74 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $5 | -100.0% | 212 | -77.7% | 0.00% | – |
Q1 2022 | $16,000 | -69.8% | 951 | -60.9% | 0.00% | – |
Q4 2021 | $53,000 | +76.7% | 2,435 | +80.1% | 0.00% | – |
Q4 2020 | $30,000 | -95.7% | 1,352 | -97.1% | 0.00% | -100.0% |
Q2 2020 | $691,000 | +215.5% | 46,663 | +132.8% | 0.00% | – |
Q1 2020 | $219,000 | -38.8% | 20,046 | -50.9% | 0.00% | -100.0% |
Q4 2019 | $358,000 | +411.4% | 40,826 | +441.2% | 0.00% | – |
Q2 2019 | $70,000 | +288.9% | 7,544 | +119.9% | 0.00% | – |
Q1 2019 | $18,000 | +200.0% | 3,430 | +122.2% | 0.00% | – |
Q4 2018 | $6,000 | -95.9% | 1,544 | -91.6% | 0.00% | – |
Q3 2018 | $148,000 | +4833.3% | 18,438 | +3609.9% | 0.00% | – |
Q2 2018 | $3,000 | – | 497 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |